# Research Paper Strategy: Clinical Trial Matching System

**Date:** November 7, 2024
**Status:** Pre-experimental analysis

---

## EXECUTIVE SUMMARY

**Decision: TEST NOW with current knowledge base, then do targeted improvements**

**Reasoning:**
1. Your KB is "good enough" for initial validation (guidelines + FDA labels)
2. Testing reveals failure modes → guides data-driven improvements
3. You have solid evaluation infrastructure already
4. Blind improvement wastes time

**Recommended Timeline:** 8 weeks to submission-ready paper

---

## I. CURRENT ARCHITECTURE ASSESSMENT

### What You HAVE Built ✅

**1. Multi-Agent State Machine Architecture**
- WorkflowEngine orchestrates 3 phases:
  - Phase 1: Patient Profiling (extract structured data)
  - Phase 2: Trial Discovery (API search + keyword ranking)
  - Phase 3: Knowledge Enhancement (RAG-based re-ranking)
- 5 state machines with 20+ states total
- ~1,000 lines of core logic
- **Novel:** State-based decomposition of trial matching

**2. Knowledge Base (Post-Cleanup)**
- NCCN guidelines: 44MB
- FDA drug labels: 20MB
- Biomarker guides: 8KB
- Total vectorstore: 22MB (was 112MB)
- **Novel:** Systematic knowledge curation, removed noisy trial corpus

**3. Evaluation Framework**
- 5 curated test cases with ground truth
- Metrics: Precision@K (K=1,3,5,10), MRR, Hit Rate
- 14 RAG configurations for ablation studies
- Infrastructure for A/B testing
- **Strong:** Rigorous evaluation design

### What You DON'T Have (Yet) ❌

1. Large test set (5 cases → need 20-50 minimum)
2. Published trial results (NEJM/JCO papers)
3. Biomarker actionability DB (OncoKB/CIViC)
4. Baseline comparisons (TF-IDF, zero-shot GPT-4)
5. Statistical significance testing

---

## II. RESEARCH CONTRIBUTION ANALYSIS

### Option A: "RAG Is Better" Paper ⚠️ RISKY

**Claim:** RAG-enhanced trial matching beats baseline methods

**Problems:**
- Somewhat obvious (reviewers expect this)
- "Why wouldn't RAG help?" → hard to justify novelty
- Needs VERY strong baselines
- Saturated area (many RAG papers)

**Verdict:** Avoid this angle unless you have exceptional results

---

### Option B: "Multi-Agent Architecture" Paper ⚠️ MEDIUM RISK

**Claim:** State machine decomposition improves trial matching

**Contribution:**
- Novel architecture (not just "LLM + RAG")
- Structured reasoning over multiple phases
- Agentic task decomposition

**Problems:**
- Reviewers will ask: "Why not just one LLM call?"
- Need ablation: Is multi-agent actually better than monolithic?
- Architecture complexity must justify itself

**Verdict:** Possible, but need strong ablation studies

---

### Option C: "Knowledge-Guided Trial Matching" Paper ✅ RECOMMENDED

**Claim:** Systematic integration of clinical guidelines + drug labels improves trial matching accuracy and interpretability

**Core Contributions:**
1. **Knowledge Curation:** Show that authoritative sources (NCCN, FDA) outperform noisy corpora
2. **Two-Stage Pipeline:** Demonstrate that broad API search + knowledge-guided re-ranking balances recall/precision
3. **Interpretability:** System provides rationale via knowledge attribution
4. **Real-World Viability:** Uses public APIs (ClinicalTrials.gov), reproducible

**Why This Works:**
- Clear problem: Trial matching is hard, real clinical need
- Non-obvious contribution: Most systems use unstructured retrieval
- Addresses practical concerns: Interpretability matters for clinicians
- Reproducible: Public data sources

**Strengths:**
- Novel knowledge integration strategy
- Practical system (not just a benchmark)
- Addresses 3 reviewer types (see Section III)
- Modest but honest claims

**Risks:** Low. Clear contribution, real problem, reproducible.

---

### Option D: "Hybrid Search Architecture" Paper ⚠️ ALTERNATIVE

**Claim:** Two-stage pipeline (API + RAG ranking) beats end-to-end retrieval

**Contribution:**
- Leverages existing trial registries (don't reinvent the wheel)
- Shows staged retrieval is better than single-pass
- Scalable to real-world deployment

**Problems:**
- Needs comparison to end-to-end retrieval
- Is two-stage really necessary? (ablation required)

**Verdict:** Possible fallback if Option C doesn't pan out

---

## III. SATISFYING THREE REVIEWER TYPES

### Reviewer Type 1: Clinicians (Use Case Validation)

**What They Care About:**
- Does this solve a real problem?
- Would I trust this in practice?
- Are the recommendations clinically sound?

**What They Need to See:**
| Requirement | Current Status | Action Needed |
|-------------|----------------|---------------|
| Real patient scenarios | ✅ Have 5 | Expand to 20-30 diverse cases |
| Clinical ground truth | ✅ Expert-labeled trials | Validate with oncologist review |
| Biomarker matching accuracy | ❓ Untested | Measure biomarker correctness |
| Interpretability | ✅ Knowledge attribution | Show example explanations in paper |
| Error analysis | ❌ None | Classify failure modes |

**Metrics They Value:**
- Precision@3 (top 3 trials must be relevant)
- Clinical accuracy (biomarker matching, eligibility)
- Interpretability score (can clinician understand why?)

**Current Readiness:** 6/10
**Needed:** Expand test set, add clinical validation, error analysis

---

### Reviewer Type 2: LLM/AI Experts (Technical Novelty)

**What They Care About:**
- What's novel about this approach?
- Is the architecture justified?
- Are baselines strong enough?

**What They Need to See:**
| Requirement | Current Status | Action Needed |
|-------------|----------------|---------------|
| Novel architecture | ✅ Multi-agent + state machines | Explain why it's better than single-pass |
| Strong baselines | ❌ None | Implement 3-4 baselines (see below) |
| Ablation studies | ✅ Infrastructure ready | Run Experiment 1 (knowledge ablation) |
| RAG vs. no RAG | ✅ Can test now | Run control experiments |
| Prompt engineering | ✅ Documented | Show prompt design in appendix |

**Baselines Required:**
1. **Keyword Search Only:** ClinicalTrials.gov API, no ranking
2. **TF-IDF Similarity:** Vector similarity between patient profile and trial descriptions
3. **Zero-Shot GPT-4:** Single prompt, no RAG, no multi-agent
4. **RAG-Enhanced (Your System):** Full pipeline

**Metrics They Value:**
- Precision@K, MRR, NDCG@K
- Retrieval quality (are relevant trials retrieved?)
- Statistical significance (t-tests, confidence intervals)

**Current Readiness:** 5/10
**Needed:** Implement baselines, run ablations, statistical testing

---

### Reviewer Type 3: Data Scientists (Quantitative Rigor)

**What They Care About:**
- Are results statistically significant?
- Is the evaluation rigorous?
- Can this be reproduced?

**What They Need to See:**
| Requirement | Current Status | Action Needed |
|-------------|----------------|---------------|
| Large test set | ❌ Only 5 cases | Expand to 20-50 cases minimum |
| Statistical significance | ❌ No tests | Add t-tests, confidence intervals |
| Cross-validation | ❌ None | Consider k-fold or leave-one-out |
| Reproducibility | ✅ Public data | Document data sources, seeds |
| Aggregate metrics | ✅ Infrastructure | Compute mean, std dev, CI |

**Metrics They Value:**
- Mean Average Precision (MAP)
- Statistical significance (p-values)
- Effect size (Cohen's d)
- Confidence intervals

**Current Readiness:** 4/10
**Needed:** Larger test set, statistical testing, reproducibility documentation

---

## IV. RECOMMENDED BASELINES

You mentioned comparing:
1. RAG-enhanced search (your system)
2. TF-IDF vector search
3. LLM general search

Here's how to implement them fairly:

### Baseline 1: Keyword Search (API Only)

**What:** ClinicalTrials.gov API search, no re-ranking

**Implementation:**
- Use Phase 2 only (Trial Discovery)
- Skip Phase 3 (Knowledge Enhancement)
- Return trials in API-provided order

**Why:** Shows value of knowledge-guided re-ranking

---

### Baseline 2: TF-IDF Vector Similarity

**What:** Classic IR approach, no LLM, no RAG

**Implementation:**
```python
from sklearn.feature_extraction.text import TfidfVectorizer
from sklearn.metrics.pairwise import cosine_similarity

# 1. Build corpus: All trial descriptions
# 2. Patient query: Concatenate diagnoses + biomarkers
# 3. Compute TF-IDF vectors
# 4. Rank by cosine similarity
```

**Why:** Shows that LLM reasoning adds value

---

### Baseline 3: Zero-Shot GPT-4 (No RAG)

**What:** Single LLM call, no knowledge base, no multi-agent

**Implementation:**
```python
prompt = f"""
Patient: {patient_profile}
Trials: {all_trials}

Rank these trials by relevance (1-10). Return JSON: [{{"nct_id": ..., "score": ...}}, ...]
"""
```

**Why:** Shows value of knowledge grounding (RAG)

---

### Baseline 4: Your System (RAG + Multi-Agent)

**What:** Full pipeline (Phase 1 + 2 + 3)

**Why:** This is your best configuration

---

### Strong Baseline: BM25 + Re-ranker

**What:** BM25 retrieval + cross-encoder re-ranking

**Implementation:**
- Use BM25 for initial retrieval (like Elasticsearch)
- Re-rank with `cross-encoder/ms-marco-MiniLM-L-6-v2`

**Why:** Industry-standard strong baseline

**Priority:** Medium (add if you have time)

---

## V. EVALUATION FRAMEWORK FOR YOUR PAPER

### Primary Research Questions

**RQ1:** Does RAG-based knowledge enhancement improve trial ranking accuracy?
- **Test:** Compare Baseline 3 (Zero-shot GPT-4) vs. Baseline 4 (Your system)
- **Metric:** Precision@3, MRR
- **Hypothesis:** RAG improves P@3 by 15-25%

**RQ2:** Which knowledge sources contribute most to accuracy?
- **Test:** Ablation study (Experiment 1 from rag_configurations.py)
- **Configs:** Guidelines only, FDA only, Both, Neither
- **Metric:** Precision@3
- **Hypothesis:** Guidelines + FDA > either alone

**RQ3:** Does multi-stage pipeline outperform single-pass retrieval?
- **Test:** Two-stage (API + RAG) vs. End-to-end retrieval
- **Metric:** Recall@10 (stage 1), Precision@3 (stage 2)
- **Hypothesis:** Two-stage balances recall/precision

---

### Metrics (In Order of Importance for Paper)

**Primary Metrics:**
1. **Precision@3** - Most important for clinicians (top 3 must be relevant)
2. **MRR** - Measures if ground truth appears early
3. **Hit Rate** - % of patients with ≥1 ground truth in top K

**Secondary Metrics:**
4. **NDCG@5** - Graded relevance (if you have relevance scores)
5. **Recall@10** - Did we retrieve ground truth at all?

**Tertiary Metrics:**
6. **Biomarker Match Rate** - % of recommendations with correct biomarker eligibility
7. **Interpretability** - Can system explain its rankings? (qualitative)

---

### Test Set Size Requirements

| Goal | Minimum Cases | Recommended |
|------|---------------|-------------|
| Proof of concept | 5 | 10 |
| Conference paper | 20 | 30-50 |
| Journal paper | 50 | 100+ |

**Your Current:** 5 cases
**Recommended for initial paper:** 20-30 cases
**How to expand:**
- Create 15 more synthetic profiles (diverse cancer types, biomarkers)
- Use GPT-4 to generate realistic profiles
- Have oncologist validate ground truth

---

## VI. DECISION: TEST NOW OR IMPROVE KB FIRST?

### My Recommendation: **TEST NOW** ✅

**Phase 1 (Week 1-2): Baseline Experiment**
**Goal:** Understand where you currently stand

**Tasks:**
1. Expand test set to 20 cases (add 15 more profiles)
2. Implement 3 baselines (Keyword, TF-IDF, Zero-shot GPT-4)
3. Run current system on all 20 cases
4. Compute Precision@3, MRR for all 4 methods
5. **Identify failure modes** (this is key!)

**Deliverable:** "Current system achieves X% P@3, Y% better than zero-shot, Z% better than keyword search"

**Time:** ~2 weeks

---

**Phase 2 (Week 3-4): Targeted KB Improvements**
**Goal:** Fix identified failure modes

**Data-Driven Approach:**
- If biomarker matching fails → Add OncoKB/CIViC
- If eligibility rules fail → Add curated eligibility corpus
- If guideline retrieval weak → Add published trial results
- If RAG retrieves wrong info → Improve chunking/indexing

**Tasks:**
1. Analyze failure modes from Phase 1
2. Add 1-2 high-value knowledge sources
3. Re-run experiments
4. Measure improvement

**Deliverable:** "Adding X improved P@3 by Y%"

**Time:** ~2 weeks

---

**Phase 3 (Week 5-6): Ablation Studies & Statistical Testing**
**Goal:** Rigorous evaluation

**Tasks:**
1. Run Experiment 1 (knowledge ablation)
2. Test with/without RAG
3. Test with/without multi-agent
4. Compute statistical significance (t-tests)
5. Error analysis, case studies

**Deliverable:** "RAG improves P@3 by X% (p < 0.05, Cohen's d = Y)"

**Time:** ~2 weeks

---

**Phase 4 (Week 7-8): Paper Writing & Visualization**
**Goal:** Submission-ready manuscript

**Tasks:**
1. Draft abstract, intro, related work
2. Create figures:
   - Precision@K curves (your system vs. baselines)
   - Ablation study bar charts
   - Confusion matrix (which biomarkers work well?)
   - Example case study with knowledge attribution
3. Error analysis section
4. Discussion, limitations, future work

**Deliverable:** Camera-ready paper

**Time:** ~2 weeks

---

## VII. ABSTRACT PREVIEW (Intellectually Honest)

Here's what your abstract could look like:

---

**Knowledge-Guided Clinical Trial Matching: A Multi-Agent System Integrating Clinical Guidelines and Biomarker Intelligence**

**Abstract**

Clinical trial matching is a critical yet challenging task in precision oncology, requiring integration of patient-specific biomarkers, treatment history, and eligibility criteria. Existing approaches rely on keyword search or generic retrieval methods that lack domain-specific knowledge. We present a multi-agent system that systematically integrates authoritative clinical knowledge—including NCCN treatment guidelines and FDA drug labels—to improve trial matching accuracy.

Our system employs a two-stage pipeline: (1) broad retrieval via the ClinicalTrials.gov API, followed by (2) knowledge-guided re-ranking using retrieval-augmented generation (RAG). We evaluate our approach on 20 diverse oncology cases with expert-labeled ground truth trials, comparing against keyword search, TF-IDF similarity, and zero-shot large language model (LLM) baselines.

Results show that our knowledge-guided approach achieves X% Precision@3 (vs. Y% for zero-shot LLM, Z% for keyword search), representing a A% relative improvement. Ablation studies demonstrate that clinical guidelines + FDA labels provide the highest accuracy, while unstructured trial corpora add noise. Our system provides interpretable recommendations through knowledge attribution, addressing a key barrier to clinical adoption.

We discuss failure modes, limitations, and future directions including integration of published trial outcomes and biomarker actionability databases. Code, evaluation data, and knowledge base curation scripts are publicly available.

---

**What This Abstract Does Well:**
- ✅ Clear problem statement
- ✅ Concrete contribution (knowledge integration)
- ✅ Honest evaluation (20 cases, compared to baselines)
- ✅ Quantitative results (X% P@3)
- ✅ Addresses interpretability
- ✅ Acknowledges limitations
- ✅ Reproducible (public code/data)

**What It Avoids:**
- ❌ Overclaiming ("revolutionary", "state-of-the-art")
- ❌ Vague contributions ("we use AI")
- ❌ Unfair baselines (comparing to weak methods)
- ❌ Cherry-picked results

---

## VIII. RISKS & MITIGATION

### Risk 1: Results Are Negative (RAG Doesn't Help)

**Likelihood:** Low (RAG usually helps)

**Mitigation:**
- Negative results are publishable! Paper becomes "When Does RAG Help?"
- Focus on ablation: Which knowledge sources matter?
- Pivot to interpretability angle

---

### Risk 2: Baselines Are Too Weak (Reviewers Complain)

**Likelihood:** Medium

**Mitigation:**
- Implement BM25 + re-ranker (strong baseline)
- Test against GPT-4 + CoT prompting (stronger baseline)
- Acknowledge in limitations: "Future work should compare to X"

---

### Risk 3: Test Set Too Small (20 Cases Insufficient)

**Likelihood:** Medium

**Mitigation:**
- Expand to 50 cases in Phase 3
- Use cross-validation
- Acknowledge limitation: "Larger validation needed"

---

### Risk 4: Reviewers Want Clinical Validation

**Likelihood:** High (for clinical journals)

**Mitigation:**
- Target AI/ML venue first (lower clinical bar)
- Get oncologist co-author to validate ground truth
- Include qualitative evaluation by clinicians

---

## IX. RECOMMENDED TARGET VENUES

### Option A: AI/ML Conference (Recommended for First Submission)

**Venues:**
- AAAI (AI for Healthcare track)
- ACL (Clinical NLP workshop)
- NeurIPS (Healthcare workshop)
- EMNLP (BioNLP workshop)

**Pros:**
- Technical novelty valued
- Faster review cycle
- Receptive to novel architectures

**Cons:**
- Less clinical impact
- Smaller audience

**Fit for your work:** 8/10

---

### Option B: Healthcare Informatics Journal

**Venues:**
- JAMIA (Journal of the American Medical Informatics Association)
- JBI (Journal of Biomedical Informatics)
- JCO Clinical Cancer Informatics

**Pros:**
- High clinical impact
- Valued by clinicians
- Longer papers allowed

**Cons:**
- Slower review (6+ months)
- Needs clinical validation
- Less receptive to pure AI

**Fit for your work:** 7/10 (after clinical validation)

---

### Option C: Hybrid (AI + Healthcare)

**Venues:**
- CHIL (Conference on Health, Inference, and Learning)
- ML4H (Machine Learning for Health)
- AIME (Artificial Intelligence in Medicine)

**Pros:**
- Values both technical + clinical
- Growing community
- Good balance

**Cons:**
- Competitive
- Needs strong story

**Fit for your work:** 9/10 ⭐ **RECOMMENDED**

---

## X. ACTIONABLE NEXT STEPS

### Immediate Actions (This Week)

1. **Expand test set to 20 cases**
   - Use evaluation/create_sample_data.py to generate 15 more
   - Diverse cancer types: breast, lung, melanoma, colorectal, etc.
   - Validate ground truth manually

2. **Implement Baseline 1: Keyword Search**
   - Modify workflow_engine.py to skip Phase 3
   - Return trials in API order

3. **Implement Baseline 3: Zero-shot GPT-4**
   - Create single-prompt ranker
   - No RAG, no multi-agent

4. **Run Initial Experiment**
   - Test all 4 methods on 20 cases
   - Compute Precision@3, MRR
   - **Identify failure modes**

---

### Decision Point 1 (End of Week 2)

**If RAG improves P@3 by >15%:**
- ✅ Strong result! Continue to Phase 2

**If RAG improves P@3 by 5-15%:**
- ⚠️ Modest result. Add targeted KB improvements (Phase 2)

**If RAG improves P@3 by <5%:**
- ❌ Weak result. Pivot to interpretability or ablation angle

---

### Decision Point 2 (End of Week 4)

**If Phase 2 improvements work:**
- ✅ Write paper emphasizing data-driven KB curation

**If Phase 2 improvements don't work:**
- ❌ Write paper as "negative result" or "when does RAG help?"

---

## XI. FINAL RECOMMENDATION

### Your Research Direction:

**Title:** Knowledge-Guided Clinical Trial Matching: A Multi-Agent System Integrating Clinical Guidelines and Biomarker Intelligence

**Contribution:** Systematic knowledge integration strategy for trial matching

**Evaluation:** 20-50 cases, 4 baselines, ablation studies, statistical testing

**Timeline:** 8 weeks to submission

**Target:** ML4H or CHIL (hybrid AI + healthcare venue)

---

### Critical Success Factors:

1. ✅ **Test NOW** - Don't wait for perfect KB
2. ✅ **Data-driven improvements** - Let failures guide you
3. ✅ **Strong baselines** - TF-IDF + Zero-shot GPT-4 minimum
4. ✅ **Honest claims** - Don't oversell
5. ✅ **Reproducibility** - Public code + data

---

### What Makes This Paper Strong:

- **Novel:** Knowledge curation strategy (not just "we use RAG")
- **Rigorous:** Multiple baselines, ablations, statistical tests
- **Honest:** Acknowledges limitations, negative results
- **Practical:** Uses public APIs, reproducible
- **Interpretable:** Knowledge attribution for clinical trust

---

### What You Should NOT Do:

- ❌ Wait for perfect KB before testing
- ❌ Claim "state-of-the-art" without large-scale validation
- ❌ Compare only to weak baselines
- ❌ Oversell RAG as magic
- ❌ Ignore interpretability

---

## XII. QUESTIONS FOR YOU

Before I implement the testing pipeline, I need to know:

1. **Timeline:** Do you have 8 weeks? Or longer/shorter?

2. **Target Venue:** AI conference (fast, technical) or journal (slow, clinical)?

3. **Co-authors:** Do you have an oncologist to validate ground truth?

4. **Compute Budget:** OpenAI API costs for 20 cases × 4 methods = ~$20-50. Acceptable?

5. **Priority:** Do you want to prioritize technical novelty (multi-agent) or practical impact (knowledge integration)?

---

Let me know your answers, and I'll:
1. Expand the test set to 20 cases
2. Implement the 3 baselines
3. Run the initial experiment
4. Give you data-driven recommendations for KB improvements

**The research direction is clear. Let's start testing.**
